{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:09:10Z","timestamp":1792440550220,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,10,30]],"date-time":"2015-10-30T00:00:00Z","timestamp":1446163200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s00228-015-1965-1","type":"journal-article","created":{"date-parts":[[2015,10,30]],"date-time":"2015-10-30T01:11:35Z","timestamp":1446167495000},"page":"175-184","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol"],"prefix":"10.1007","volume":"72","author":[{"given":"Patteet","family":"Lisbeth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haufroid","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maudens","family":"Kristof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabbe","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morrens","family":"Manuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neels","family":"Hugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,30]]},"reference":[{"issue":"6","key":"1965_CR1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","volume":"44","author":"C Hiemke","year":"2011","unstructured":"Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Grunder G, Haen E, Havemann-Reinecke U, Jaquenoud Sirot E, Kirchherr H, Laux G, Lutz UC, Messer T, Muller MJ, Pfuhlmann B, Rambeck B, Riederer P, Schoppek B, Stingl J, Uhr M, Ulrich S, Waschgler R, Zernig G (2011) AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44(6):195\u2013235","journal-title":"Pharmacopsychiatry"},{"key":"1965_CR2","doi-asserted-by":"crossref","unstructured":"Haufroid V, Hantson P (2015) CYP2D6 genetic polymorphisms and their relevance for poisoning due to amphetamines, opioid analgesics and antidepressants. Clin Toxicol (Phila):1\u201310. doi:10.3109\/15563650.2015.1049355","DOI":"10.3109\/15563650.2015.1049355"},{"key":"1965_CR3","unstructured":"nomenclature CDa (Last accessed on June 2015) CYP2D6 Allele nomenclature. http:\/\/www.cypalleles.ki.se\/cyp2d6.htm ."},{"issue":"4","key":"1965_CR4","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/FTD.0b013e3181e1a78d","volume":"32","author":"W Steimer","year":"2010","unstructured":"Steimer W (2010) Pharmacogenetics and psychoactive drug therapy: ready for the patient? Ther Drug Monit 32(4):381\u2013386. doi: 10.1097\/FTD.0b013e3181e1a78d","journal-title":"Ther Drug Monit"},{"issue":"4","key":"1965_CR5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.tips.2004.02.007","volume":"25","author":"M Ingelman-Sundberg","year":"2004","unstructured":"Ingelman-Sundberg M (2004) Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 25(4):193\u2013200. doi: 10.1016\/j.tips.2004.02.007","journal-title":"Trends Pharmacol Sci"},{"issue":"6","key":"1965_CR6","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2217\/pgs.15.13","volume":"16","author":"MV Antunes","year":"2015","unstructured":"Antunes MV, de Oliveira V, Raymundo S, Staudt DE, Gossling G, Biazus JV, Cavalheiro JA, Rosa DD, Mathy G, Wallemacq P, Linden R, Schwartsmann G, Haufroid V (2015) CYP3A4*22 is related to increased plasma levels of 4-hydroxytamoxifen and partially compensates for reduced CYP2D6 activation of tamoxifen. Pharmacogenomics 16(6):601\u2013617. doi: 10.2217\/pgs.15.13","journal-title":"Pharmacogenomics"},{"issue":"5","key":"1965_CR7","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/sj.mp.4001494","volume":"9","author":"J Kirchheiner","year":"2004","unstructured":"Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, Brockmoller J (2004) Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9(5):442\u2013473. doi: 10.1038\/sj.mp.4001494","journal-title":"Mol Psychiatry"},{"issue":"11","key":"1965_CR8","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00228-005-0044-4","volume":"61","author":"HR Luo","year":"2005","unstructured":"Luo HR, Gaedigk A, Aloumanis V, Wan YJ (2005) Identification of CYP2D6 impaired functional alleles in Mexican Americans. Eur J Clin Pharmacol 61(11):797\u2013802. doi: 10.1007\/s00228-005-0044-4","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"1965_CR9","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1067\/mcp.2002.127494","volume":"72","author":"J Brockmoller","year":"2002","unstructured":"Brockmoller J, Kirchheiner J, Schmider J, Walter S, Sachse C, Muller-Oerlinghausen B, Roots I (2002) The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 72(4):438\u2013452. doi: 10.1067\/mcp.2002.127494","journal-title":"Clin Pharmacol Ther"},{"key":"1965_CR10","first-page":"52","volume":"33","author":"RHN Schaick van","year":"2008","unstructured":"van Schaick RHN, Grandia L, de Goede A, Bet PM, Bekers O, Guchelaar HJ, Goldschmidt HMJ, Meijer MMC, Mulder H, van Der Weide J, Deneer VHM (2008) Nederlandse consensus: CYP2D6 genotype '1-0' ingedeeld als intermediaire metaboliseerder. Ned Tijdschr Klin Chem Labgeneesk 33:52\u201353","journal-title":"Ned Tijdschr Klin Chem Labgeneesk"},{"issue":"1","key":"1965_CR11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1046\/j.1365-2125.2001.01313.x","volume":"51","author":"JG Shin","year":"2001","unstructured":"Shin JG, Kane K, Flockhart DA (2001) Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol. Br J Clin Pharmacol 51(1):45\u201352","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"1965_CR12","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2165\/00003088-199937060-00001","volume":"37","author":"S Kudo","year":"1999","unstructured":"Kudo S, Ishizaki T (1999) Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet 37(6):435\u2013456. doi: 10.2165\/00003088-199937060-00001","journal-title":"Clin Pharmacokinet"},{"key":"1965_CR13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cca.2013.11.024","volume":"429","author":"L Patteet","year":"2014","unstructured":"Patteet L, Maudens KE, Sabbe B, Morrens M, De Doncker M, Neels H (2014) High throughput identification and quantification of 16 antipsychotics and 8 major metabolites in serum using ultra-high performance liquid chromatography-tandem mass spectrometry. Clin Chim Acta 429:51\u201358. doi: 10.1016\/j.cca.2013.11.024","journal-title":"Clin Chim Acta"},{"issue":"2","key":"1965_CR14","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/sj.clpt.6100406","volume":"83","author":"A Gaedigk","year":"2008","unstructured":"Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS (2008) The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 83(2):234\u2013242. doi: 10.1038\/sj.clpt.6100406","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1965_CR15","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/0091270009359182","volume":"50","author":"S Borges","year":"2010","unstructured":"Borges S, Desta Z, Jin Y, Faouzi A, Robarge JD, Philips S, Nguyen A, Stearns V, Hayes D, Rae JM, Skaar TC, Flockhart DA, Li L (2010) Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol 50(4):450\u2013458. doi: 10.1177\/0091270009359182","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"1965_CR16","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/clpt.2011.287","volume":"91","author":"KR Crews","year":"2012","unstructured":"Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT, Kharasch ED, Skaar TC (2012) Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther 91(2):321\u2013326. doi: 10.1038\/clpt.2011.287","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"1965_CR17","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00228-007-0373-6","volume":"63","author":"M Hendset","year":"2007","unstructured":"Hendset M, Hermann M, Lunde H, Refsum H, Molden E (2007) Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole. Eur J Clin Pharmacol 63(12):1147\u20131151. doi: 10.1007\/s00228-007-0373-6","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1965_CR18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00702-014-1300-5","volume":"122","author":"E Spina","year":"2015","unstructured":"Spina E, de Leon J (2015) Clinical applications of CYP genotyping in psychiatry. J Neural Transm 122(1):5\u201328. doi: 10.1007\/s00702-014-1300-5","journal-title":"J Neural Transm"},{"issue":"5","key":"1965_CR19","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/clpt.2011.34","volume":"89","author":"JJ Swen","year":"2011","unstructured":"Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ, van der Weide J, Wilffert B, Deneer VH, Guchelaar HJ (2011) Pharmacogenetics: from bench to byte\u2014an update of guidelines. Clin Pharmacol Ther 89(5):662\u2013673. doi: 10.1038\/clpt.2011.34","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1965_CR20","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s40291-013-0028-5","volume":"17","author":"CF Samer","year":"2013","unstructured":"Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA (2013) Applications of CYP450 testing in the clinical setting. Molecular Diagnosis & therapy 17(3):165\u2013184. doi: 10.1007\/s40291-013-0028-5","journal-title":"Molecular Diagnosis & therapy"},{"issue":"6","key":"1965_CR21","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1365-2125.1991.tb05588.x","volume":"31","author":"RF Tyndale","year":"1991","unstructured":"Tyndale RF, Kalow W, Inaba T (1991) Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine\/debrisoquine monooxygenase). Br J Clin Pharmacol 31(6):655\u2013660","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"1965_CR22","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s002280050679","volume":"55","author":"L Pan","year":"1999","unstructured":"Pan L, Belpaire FM (1999) In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol. Eur J Clin Pharmacol 55(8):599\u2013604","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"1965_CR23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/JCP.0000000000000319","volume":"35","author":"K Weide van der","year":"2015","unstructured":"van der Weide K, van der Weide J (2015) The influence of the CYP3A4*22 polymorphism and CYP2D6 polymorphisms on serum concentrations of aripiprazole, haloperidol, pimozide, and risperidone in psychiatric patients. J Clin Psychopharmacol 35(3):228\u2013236. doi: 10.1097\/JCP.0000000000000319","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"1965_CR24","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/FTD.0b013e3182708ec5.","volume":"34","author":"L Patteet","year":"2012","unstructured":"Patteet L, Morrens M, Maudens KE, Niemegeers P, Sabbe B, Neels H (2012) Therapeutic drug monitoring of common antipsychotics. Ther Drug Monit 34(6):629\u2013651. doi: 10.1097\/FTD.0b013e3182708ec5","journal-title":"Ther Drug Monit"},{"issue":"2","key":"1965_CR25","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0378-4347(94)00134-0","volume":"656","author":"M Aravagiri","year":"1994","unstructured":"Aravagiri M, Marder SR, Van Putten T, Marshall BD (1994) Simultaneous determination of plasma haloperidol and its metabolite reduced haloperidol by liquid chromatography with electrochemical detection. Plasma levels in schizophrenic patients treated with oral or intramuscular depot haloperidol. J Chromatogr B Biomed Appl 656(2):373\u2013381","journal-title":"J Chromatogr B Biomed Appl"},{"issue":"2","key":"1965_CR26","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/00007691-199804000-00015","volume":"20","author":"L Pan","year":"1998","unstructured":"Pan L, Rosseel MT, Belpaire FM (1998) Comparison of two high-performance liquid chromatographic methods for monitoring plasma concentrations of haloperidol and reduced haloperidol. Ther Drug Monit 20(2):224\u2013230","journal-title":"Ther Drug Monit"},{"issue":"7","key":"1965_CR27","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1211\/jpp.58.7.0001","volume":"58","author":"M Murray","year":"2006","unstructured":"Murray M (2006) Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. J Pharm Pharmacol 58(7):871\u2013885. doi: 10.1211\/jpp.58.7.0001","journal-title":"J Pharm Pharmacol"},{"issue":"6","key":"1965_CR28","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/JCP.0b013e3181c17df0","volume":"29","author":"M Hendset","year":"2009","unstructured":"Hendset M, Molden E, Refsum H, Hermann M (2009) Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone. J Clin Psychopharmacol 29(6):537\u2013541. doi: 10.1097\/JCP.0b013e3181c17df0","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"1965_CR29","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/FTD.0b013e3181858ca9","volume":"30","author":"A Gunes","year":"2008","unstructured":"Gunes A, Spina E, Dahl ML, Scordo MG (2008) ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety. Ther Drug Monit 30(5):628\u2013633. doi: 10.1097\/FTD.0b013e3181858ca9","journal-title":"Ther Drug Monit"},{"issue":"1","key":"1965_CR30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4088\/JCP.v66n0103","volume":"66","author":"J Leon de","year":"2005","unstructured":"de Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ (2005) The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. The Journal of Clinical psychiatry 66(1):15\u201327","journal-title":"The Journal of Clinical psychiatry"},{"issue":"6","key":"1965_CR31","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/00007691-199612000-00001","volume":"18","author":"K Linnet","year":"1996","unstructured":"Linnet K, Wiborg O (1996) Influence of Cyp2D6 genetic polymorphism on ratios of steady-state serum concentration to dose of the neuroleptic zuclopenthixol. Ther Drug Monit 18(6):629\u2013634","journal-title":"Ther Drug Monit"},{"issue":"4","key":"1965_CR32","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0009-9236(96)90111-3","volume":"59","author":"M Jerling","year":"1996","unstructured":"Jerling M, Dahl ML, Aberg-Wistedt A, Liljenberg B, Landell NE, Bertilsson L, Sjoqvist F (1996) The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clin Pharmacol Ther 59(4):423\u2013428. doi: 10.1016\/S0009-9236(96)90111-3","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1965_CR33","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00213-002-1059-5","volume":"162","author":"P Jaanson","year":"2002","unstructured":"Jaanson P, Marandi T, Kiivet RA, Vasar V, Vaan S, Svensson JO, Dahl ML (2002) Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype. Psychopharmacology 162(1):67\u201373. doi: 10.1007\/s00213-002-1059-5","journal-title":"Psychopharmacology"}],"updated-by":[{"DOI":"10.1007\/s00228-016-2144-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,10,13]],"date-time":"2016-10-13T00:00:00Z","timestamp":1476316800000}}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-015-1965-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-015-1965-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-015-1965-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:49:15Z","timestamp":1558702155000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-015-1965-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,30]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["1965"],"URL":"https:\/\/doi.org\/10.1007\/s00228-015-1965-1","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00228-016-2144-8","asserted-by":"object"}]},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,30]]}}}